6.
Buja L, Ferrans V, Graw Jr R
. Cardiac pathologic findings in patients treated with bone marrow transplantation. Hum Pathol. 1976; 7(1):17-45.
DOI: 10.1016/s0046-8177(76)80004-4.
View
7.
Rotz S, Ryan T, Jodele S, Jefferies J, Lane A, Pate A
. The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults. Bone Marrow Transplant. 2017; 52(8):1171-1179.
DOI: 10.1038/bmt.2017.62.
View
8.
Rotz S, Ryan T, Hayek S
. Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. J Thromb Thrombolysis. 2020; 51(4):854-869.
PMC: 8085022.
DOI: 10.1007/s11239-020-02344-9.
View
9.
Dulery R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E
. Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation. JACC CardioOncol. 2021; 3(2):250-259.
PMC: 8352028.
DOI: 10.1016/j.jaccao.2021.02.011.
View
10.
Yeh J, Whited L, Saliba R, Rondon G, Banchs J, Shpall E
. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021; 5(24):5599-5607.
PMC: 8714723.
DOI: 10.1182/bloodadvances.2021004846.
View
11.
Duncan C, Brazauskas R, Huang J, Shaw B, Majhail N, Savani B
. Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018; 53(10):1278-1287.
PMC: 6158112.
DOI: 10.1038/s41409-018-0155-z.
View
12.
Johansson T, Partanen J, Saavalainen P
. HLA allele-specific expression: Methods, disease associations, and relevance in hematopoietic stem cell transplantation. Front Immunol. 2022; 13:1007425.
PMC: 9554311.
DOI: 10.3389/fimmu.2022.1007425.
View
13.
Hertenstein B, Stefanic M, Schmeiser T, Scholz M, Goller V, Clausen M
. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol. 1994; 12(5):998-1004.
DOI: 10.1200/JCO.1994.12.5.998.
View
14.
Perez-Valencia A, Cascos E, Carbonell-Ordeig S, Charry P, Gomez-Hernando M, Rodriguez-Lobato L
. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant. Blood Adv. 2022; 7(10):2018-2031.
PMC: 10188633.
DOI: 10.1182/bloodadvances.2022008792.
View
15.
Alblooshi R, Kanfar S, Lord B, Atenafu E, Michelis F, Pasic I
. Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. Eur J Haematol. 2020; 106(1):32-39.
DOI: 10.1111/ejh.13482.
View
16.
Armenian S, Yang D, Teh J, Atencio L, Gonzales A, Wong F
. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv. 2018; 2(14):1756-1764.
PMC: 6058239.
DOI: 10.1182/bloodadvances.2018019117.
View
17.
Leger K, Baker K, Cushing-Haugen K, Flowers M, Leisenring W, Martin P
. Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer. 2018; 124(7):1507-1515.
PMC: 5867247.
DOI: 10.1002/cncr.31227.
View
18.
Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M
. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007; 110(9):3463-71.
DOI: 10.1182/blood-2006-10-054080.
View
19.
Uderzo C, Pillon M, Corti P, Tridello G, Tana F, Zintl F
. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of.... Bone Marrow Transplant. 2007; 39(11):667-75.
DOI: 10.1038/sj.bmt.1705652.
View
20.
Kurauchi K, Nishikawa T, Miyahara E, Okamoto Y, Kawano Y
. Role of metabolites of cyclophosphamide in cardiotoxicity. BMC Res Notes. 2017; 10(1):406.
PMC: 5557551.
DOI: 10.1186/s13104-017-2726-2.
View